When most people think about longevity interventions, they think supplements, exercise, sleep. Vaccines are rarely in the conversation. They should be. The data on Shingrix (the shingles vaccine) and cardiovascular protection is one of the most underreported longevity stories of the last few years.
What Is Shingrix?
Shingrix is the recombinant zoster vaccine (RZV) approved in 2017 that replaced Zostavax. It prevents shingles — the reactivation of the varicella-zoster virus that lies dormant in nerve ganglia after initial chickenpox infection. Recommended for adults 50+, two doses 2-6 months apart, with ~90%+ efficacy at preventing shingles.
The shingles prevention alone is worth it — shingles is extremely painful, can cause permanent nerve damage (postherpetic neuralgia), and affects about 1 in 3 Americans in their lifetime. But the story gets more interesting.
The Cardiovascular Protection Data
A 2024 study published in the European Heart Journal followed 1.27 million adults in South Korea who received zoster vaccines. The findings:
- Shingrix recipients had a 23% lower risk of major cardiovascular events (heart attack, heart failure, stroke) compared to unvaccinated individuals
- The protection lasted at least 8 years in follow-up
- The effect was most pronounced in men, adults 60-79, and people with unhealthy lifestyle risk factors
A separate 2023 study in Nature linked varicella-zoster virus reactivation to increased cardiovascular risk through mechanisms including endothelial inflammation and arterial wall changes. The hypothesis: herpes zoster reactivation causes vascular inflammation. Preventing reactivation via vaccination prevents that inflammatory cascade — and the downstream cardiovascular events it accelerates.
The Broader Vaccine-Longevity Connection
This is part of a pattern researchers are increasingly noticing:
- Influenza vaccination has been associated in multiple observational studies with reduced all-cause mortality in older adults — beyond what you'd expect from flu prevention alone.
- COVID vaccination studies have shown reduced risk of post-COVID cardiovascular events in subsequent variants.
- HPV vaccination data shows long-term cervical cancer prevention across decades of follow-up.
The mechanism connecting vaccines to broader longevity effects is likely chronic inflammation. Many viruses that cause acute illness can persist at low levels or cause periodic reactivations that drive chronic vascular inflammation. Preventing reactivation removes a chronic inflammatory stressor.
Who Should Get Shingrix
Per CDC guidelines: all adults 50+ (two doses). Also recommended for adults 19+ who are immunocompromised. If you got the old Zostavax before 2017, you should get Shingrix — it's dramatically more effective. Where to get it: Most pharmacies carry it. Medicare Part D and most private insurance cover it at 50+. Out of pocket: ~$200-350 for both doses.
Other Vaccines Worth Discussing at Your Annual Physical
- Tdap (tetanus/diphtheria/pertussis): Every 10 years. Often forgotten by adults.
- RSV vaccine (Abrysvo/Mresvia): Newly approved (2023-2024) for adults 60+. RSV causes significant mortality in older adults. A one-time dose.
- Pneumococcal (Prevnar 20): For adults 65+ or younger adults with certain risk factors.
- Annual flu shot: The cardiovascular data is increasingly compelling for adults with existing cardiovascular risk.
The Longevity Framework Shift
Most longevity interventions reduce ongoing stressors — inflammation, oxidative stress, metabolic dysfunction. Vaccines fit this framework. They prevent acute infectious events that cause vascular damage and inflammation that ages you.
For context: the 23% cardiovascular risk reduction from Shingrix is comparable to the effect size of statin therapy for primary prevention. You'd take a statin for that effect. You should take Shingrix. If you want to understand your cardiovascular baseline first: Marek Health provides comprehensive cardiovascular panels including ApoB, Lp(a), hsCRP, and other markers.